CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types

Peer Review reports

Original Submission
25 May 2023	Submitted	Original manuscript
16 Jun 2023	Reviewed	Reviewer Report
2 Oct 2023	Reviewed	Reviewer Report - Pooria Safarzadeh Kozani
17 Nov 2023	Author responded	Author comments - Eloah Rabello Suarez
23 Nov 2023	Author responded	Author comments - Eloah Rabello Suarez
Resubmission - Version 2
17 Nov 2023	Submitted	Manuscript version 2
12 Feb 2024	Reviewed	Reviewer Report - Pooria Safarzadeh Kozani
28 May 2024	Reviewed	Reviewer Report
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
16 Jul 2024	Editorially accepted
22 Aug 2024	Article published	10.1186/s12885-024-12651-6

Back to article page